You are here

Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy Results Confirm and Extend 40-Week Findings that Treatment with Crysvita is Superior to Conventional Therapy 
Thursday, February 14, 2019 - 08:30